DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

DNA Methyltransferase Inhibitors in Myeloid Cancer : Clonal Eradication or Clonal Differentiation? / Ørskov, Andreas Due; Grønbæk, Kirsten.

I: Cancer journal (Sudbury, Mass.), Bind 23, Nr. 5, 09.2017, s. 277-285.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Ørskov, AD & Grønbæk, K 2017, 'DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?', Cancer journal (Sudbury, Mass.), bind 23, nr. 5, s. 277-285. https://doi.org/10.1097/PPO.0000000000000282

APA

Ørskov, A. D., & Grønbæk, K. (2017). DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation? Cancer journal (Sudbury, Mass.), 23(5), 277-285. https://doi.org/10.1097/PPO.0000000000000282

Vancouver

Ørskov AD, Grønbæk K. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation? Cancer journal (Sudbury, Mass.). 2017 sep.;23(5):277-285. https://doi.org/10.1097/PPO.0000000000000282

Author

Ørskov, Andreas Due ; Grønbæk, Kirsten. / DNA Methyltransferase Inhibitors in Myeloid Cancer : Clonal Eradication or Clonal Differentiation?. I: Cancer journal (Sudbury, Mass.). 2017 ; Bind 23, Nr. 5. s. 277-285.

Bibtex

@article{b7c2532946934cba83601743ebe4ad53,
title = "DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?",
abstract = "DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.",
author = "{\O}rskov, {Andreas Due} and Kirsten Gr{\o}nb{\ae}k",
year = "2017",
month = sep,
doi = "10.1097/PPO.0000000000000282",
language = "English",
volume = "23",
pages = "277--285",
journal = "Cancer Journal",
issn = "1528-9117",
publisher = "Lippincott Williams & Wilkins",
number = "5",

}

RIS

TY - JOUR

T1 - DNA Methyltransferase Inhibitors in Myeloid Cancer

T2 - Clonal Eradication or Clonal Differentiation?

AU - Ørskov, Andreas Due

AU - Grønbæk, Kirsten

PY - 2017/9

Y1 - 2017/9

N2 - DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.

AB - DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.

U2 - 10.1097/PPO.0000000000000282

DO - 10.1097/PPO.0000000000000282

M3 - Review

C2 - 28926428

VL - 23

SP - 277

EP - 285

JO - Cancer Journal

JF - Cancer Journal

SN - 1528-9117

IS - 5

ER -

ID: 185839308